Patient Groups Want More Say In Talks On New UK Pricing Deal
The Association of the British Pharmaceutical Industry has welcomed calls from three patient group umbrella organizations to be more involved as the UK government negotiates with the ABPI on a successor to the 2019 voluntary pricing scheme.
You may also be interested in...
Legal Challenge Could Put UK Drug Pricing Deal At Risk
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.
Mixed Support For ABPI's UK Price Scheme Proposals
The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.
Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.